RS BioTherapeutics
Private Company
Funding information not available
Overview
RS BioTherapeutics is a private, pre-revenue biotech company pioneering a novel approach to treating pulmonary inflammatory diseases. Its core asset, RSBT-001, is a first-in-class therapeutic leveraging specific, immune-modulating cannabinoids to target inflammation in the lungs, with an initial focus on chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and pulmonary arterial hypertension (PAH). The company is in the preclinical stage, targeting an Investigational New Drug (IND) application filing in 2026, and is led by a team of industry veterans and supported by a therapeutic expert council. Its strategy aims to address a significant unmet need for non-steroidal anti-inflammatory treatments in large respiratory markets.
Technology Platform
Platform leveraging specific, anti-inflammatory cannabinoids to multi-target the inflammatory cascade in the lungs, aiming for a safer alternative to broad-acting corticosteroids.
Opportunities
Risk Factors
Competitive Landscape
The pulmonary inflammation space is competitive, with ongoing research from large pharma and biotechs on novel anti-inflammatory and anti-fibrotic agents. RSBT-001 must differentiate itself from both standard-of-care corticosteroids and these emerging therapies in development.